Look for Pharma Talent with Fleming Europe
News Feb 27, 2012
Staying competitive in the pharmaceutical industry requires the ability to bridge gaps between multi-disciplinary areas such as science, business, law and public relations. The most successful pharma and biotech companies know that behind the success is a pool of talented personnel that are able to think outside the box and adapt to an ever-evolving environment.
Fleming Europe has organized the Talent Forward 2012, its 7th edition of the successful Pharma HR series. The event will take place in the comfort of the Hotel Rey Juan Carlos I, in Barcelona on 3 – 4 May 2012.
The Masterclass session, “Aligning organizational coaching to talent management strategy,” will be the center of attention. Facilitated by Dr. Paul Turner, Honorary research fellow from Birmingham city university, UK, will concentrate on talent challenges in the pharma industry, various dimensions of talent management, and coaching & relationship management capability.
The Talent forward 2012 survey, currently available online, will conclude the afternoon session. The evaluation and results advices will be presented and discussed.
The 2-day conference will be rich in topics and will cover all the stages in the pharma talent life-cycle – innovative pharma HR talent acquisition, finding talent for special positions, developments in talent mapping, examples of the most effective talent development programs, clever talent retention and reengagement and the influence of popular social media.
Panel discussions enabling the interaction with prominent speakers from Pfizer, Sanofi Aventis, GlaxoSmithKline, Eli Lilly, Abbott, Amgen, Sandoz, Nycomed, Merck, Shire, etc. are scheduled throughout the conference.
The pharmaceutical industry of developed economies is already saturated with a dedicated workforce. In emerging markets pharma companies have to fight for qualified personnel. How to “capture & hire” is only the first step to take. How to retain such talent is the vital question these companies need to answer.
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE
1 in 3 U.S. Adults May Be Using Medications That Have Potential to Cause DepressionNews
A new study from University of Illinois at Chicago researchers suggests that more than one-third of U.S. adults may be using prescription medications that have the potential to cause depression or increase the risk of suicide.READ MORE